These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 8658627)

  • 1. An open randomized parallel group study to compare Sandimmune Neoral with Sandimmune soft gelatin capsule in stable renal transplant patients.
    Park K; Koh YB; Kwak JY; Kim SJ; Yoon YS; Kang CM; Kim YS
    Transplant Proc; 1996 Jun; 28(3):1202-3. PubMed ID: 8658627
    [No Abstract]   [Full Text] [Related]  

  • 2. Conversion from Sandimmune to Neoral in stable renal transplant recipients. Sandoz Study Group OLN-353.
    Pescovitz MD
    Transplant Proc; 1996 Aug; 28(4):2196-8. PubMed ID: 8769198
    [No Abstract]   [Full Text] [Related]  

  • 3. A randomized, controlled trial to assess the safety of switching stable renal transplant patients from Sandimmun to Sandimmun Neoral.
    Loo CS; Morad Z; Lim TO; Fan KS; Suleiman AB
    Transplant Proc; 1996 Jun; 28(3):1328-9. PubMed ID: 8658680
    [No Abstract]   [Full Text] [Related]  

  • 4. Case reports on conversion to Neoral therapy in renal transplant patients.
    Curtis JJ
    Transplant Proc; 1996 Aug; 28(4):2221-2; discussion 2218. PubMed ID: 8769205
    [No Abstract]   [Full Text] [Related]  

  • 5. Case studies: conversion from Sandimmune to Neoral in stable renal allograft recipients.
    Roth D; Miller J
    Transplant Proc; 1996 Aug; 28(4):2219-20; discussion 2218. PubMed ID: 8769204
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparison of Neoral and Sandimmune preparations in renal transplant patients--improved pharmacokinetics with neoral.
    Warrens AN; Salama A; Waters JB; Lechler RI
    Transplant Proc; 1996 Aug; 28(4):2169-70. PubMed ID: 8769190
    [No Abstract]   [Full Text] [Related]  

  • 7. Interim analysis of study OLN-356: Neoral versus Sandimmune in US primary liver transplant recipients. OLN-356 Principal Investigators.
    Pinson CW; Beauregard-Zollinger L
    Transplant Proc; 1996 Aug; 28(4):2234-6. PubMed ID: 8769209
    [No Abstract]   [Full Text] [Related]  

  • 8. Conversion from Sandimmune to Neoral in stable renal and pancreas transplant recipients enhances cyclosporine absorption.
    Chapman JR; O'Connell PJ; Bovington KJ; Allen RD
    Transplant Proc; 1996 Aug; 28(4):2293-5. PubMed ID: 8769229
    [No Abstract]   [Full Text] [Related]  

  • 9. Conversion from Sandimmune to Neoral and induction therapy with Neoral in pediatric renal transplant recipients.
    Hoyer PF; Boekenkamp A; Vester U; Offner G; Brodehl J
    Transplant Proc; 1996 Aug; 28(4):2259-61. PubMed ID: 8769218
    [No Abstract]   [Full Text] [Related]  

  • 10. Safety and tolerability of CyA microemulsion formulation (Sandimmun Neoral) in stable renal transplant patients after 24 months of treatment. German Neoral Study Group.
    Offermann G; Korn A
    Transplant Proc; 1996 Aug; 28(4):2204-6. PubMed ID: 8769201
    [No Abstract]   [Full Text] [Related]  

  • 11. Converting renal transplant patients maintained on Sandimmune to a new microemulsion formulation, Sandimmune Neoral.
    Chu SH; Pang ST; Chiang YJ; Chuang CK; Chen HW; Chen CS; Chou CC; Huang CC
    Transplant Proc; 1998 Nov; 30(7):3521-3. PubMed ID: 9838543
    [No Abstract]   [Full Text] [Related]  

  • 12. Sandimmun Neoral: Taiwanese experience in renal transplant patients with special reference to patients with existing liver disease.
    Lee PH; Hu RH; Tsai KS; Chern HD; Gau YS; Chen RR
    Transplant Proc; 1996 Jun; 28(3):1327. PubMed ID: 8658679
    [No Abstract]   [Full Text] [Related]  

  • 13. Cyclosporine pharmacokinetic profiles in stable renal allograft recipients converting from Sandimmun to Neoral.
    Vathsala A; Lee WT; Jacob E; Woo KT
    Transplant Proc; 1996 Jun; 28(3):1324-6. PubMed ID: 8658678
    [No Abstract]   [Full Text] [Related]  

  • 14. Cyclosporine pharmacokinetics in renal allograft recipients with diabetes mellitus with Sandimmune and Sandimmune Neoral.
    Serafinowicz A; Gaciong Z; Baçzkowska T; Durlik M; Lao M
    Transplant Proc; 1996 Dec; 28(6):3140-1. PubMed ID: 8962217
    [No Abstract]   [Full Text] [Related]  

  • 15. Changing stable heart transplant recipients from Sandimmune to Neoral.
    Dalrymple-Hay M; Meara M; Reynolds L; Backhouse L; Wright D; Holt D; Johnston A; Madden B; Murday A
    Transplant Proc; 1996 Aug; 28(4):2285-6. PubMed ID: 8769227
    [No Abstract]   [Full Text] [Related]  

  • 16. Experience with clinical use of Sandimmun Neoral in renal transplant patients.
    Min ZL; Zhao M; Zhu YH; Qi J; Wang LM; Wang YW
    Transplant Proc; 1996 Jun; 28(3):1356-7. PubMed ID: 8658692
    [No Abstract]   [Full Text] [Related]  

  • 17. Conversion from cyclosporine Sandimmune to cyclosporine Neoral in the stable renal transplant population.
    Griffin PJ; Moore RH; Jurewicz WA; Lord RH; Webley Y; Jenkins J
    Transplant Proc; 1997; 29(1-2):303. PubMed ID: 9123007
    [No Abstract]   [Full Text] [Related]  

  • 18. Conversion from Sandimmune to Neoral in stable heart transplant recipients.
    Pethig K; Ruhparwar A; Korn A; Christians U; Wahlers T
    Transplant Proc; 1996 Aug; 28(4):2287-9. PubMed ID: 8769228
    [No Abstract]   [Full Text] [Related]  

  • 19. Safety and tolerability of Neoral vs Sandimmune: 1-year data in primary renal allograft recipients. Neoral Study Group.
    Barone G; Bunke CM; Choc MG; Hricik DE; Jin JH; Klein JB; Marsh CL; Min DI; Pescovitz MD; Pollak R; Pruett TL; Stinson JB; Thompson JS; Vasquez E; Waid T; Wombolt DG; Wong RL
    Transplant Proc; 1996 Aug; 28(4):2183-6. PubMed ID: 8769194
    [No Abstract]   [Full Text] [Related]  

  • 20. Settling the question: Sandimmune or Neoral?
    Hull AR
    Nephrol News Issues; 1996 May; 10(5):9. PubMed ID: 8715799
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.